Drugs / [F-18]HX4
[F-18]HX4
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT02584400 | May 2016 → May 2017 | carcinoma of esophagus, metastatic malignant neoplasm in the brain, primary brain neoplasm, prostate carcinoma +1 | Maastricht Radiation Oncology | Terminated | No outcome recorded |
| Phase 2 | NCT01075399 | Feb 2010 → May 2011 | cervical cancer, head and neck cancer, liver cancer, lung cancer +1 | Siemens Molecular Imaging | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT01210131 | Jul 2013 → Jan 2014 | small cell lung carcinoma | Maastricht Radiation Oncology | Withdrawn | No outcome recorded |
| — | NCT01995084 | May 2012 → Jun 2014 | esophageal cancer, malignant pancreatic neoplasm, rectal cancer | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT01989000 Comparator | Nov 2013 → Dec 2017 | malignant pancreatic neoplasm | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [F-18]HX4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01989000 ↗ |
| Known as | 18F-HX4 | “Non-invasive imaging with positron emission tomography (PET) using the 2-nitroimidazole nucleoside analogue,...” NCT01995084 ↗ |
| Known as | 3-[18F]fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol | “[18F]HX4 is 3-[18F]fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol” NCT02584400 ↗ |
| Known as | [18F]HX4 is 3-[18F]fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol | “[18F]HX4 is 3-[18F]fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol” NCT02584400 ↗ |
| Modality | Diagnostic / imaging agent | “as a reliable non-invasive PET imaging marker for detection of tumor hypoxia regions” NCT01075399 ↗ |
| Route | Intravenous | “is administered in a single intravenous bolus injection” NCT01075399 ↗ |